FDA expands use of stool test from BD Diagnostics

01/12/2009 | Forbes

The FDA has allowed BD Diagnostics, a unit of Becton, Dickinson and Co., to sell a stool test for the "rapid detection" of a toxin that can cause clostridium difficile infection. The BD GeneOhm Cdiff molecular test, which could remove the need for multiple screenings, is already approved for use in spotting methicillin-resistant Staphylococcus aureus.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT